The National Blood Authority is responsible for ensuring the supply of blood and blood products for patient care.

This includes clotting factor and other blood products used to treat a range of bleeding disorders, such as haemophilia.

These products can be made from blood plasma through a process in which different types of proteins found in plasma are separated, purified and concentrated into therapeutic doses.

In some cases, there are recombinant product versions made from genetically engineered blood cell lines, or other synthetic products made using modern technology.

We fund a range of clotting factor and other products that the state, territory and Australian Government health ministers have agreed to make available.

This means the approved products are provided at no cost to patients based on clinical need and appropriate clinical practice and are included on the National Product Price List.

There are certain products that have specific supply and delivery arrangements. For details, please contact us.

The Therapeutic Goods Administration (TGA) regulates blood and blood components(Opens in a new tab/window) as prescription medicines. You can search the Australian Register of Therapeutic Goods(Opens in a new tab/window) for blood and blood products approved for supply in Australia.

Products we fund

Factor VIII

Concentrated coagulation factor VIII is mainly used to treat patients with haemophilia A.

In some circumstances, it may also be used for patients with:

  • factor VIII inhibitors (neutralising antibodies)
  • von Willebrand disorder.

We fund both recombinant and plasma-derived factor VIII.

Factor IX

Concentrated coagulation factor IX is used to treat patients with haemophilia B. We fund both recombinant and plasma-derived factor IX.

Factor VIIa

Recombinant activated coagulation factor VII (rFVIIa) is used for patients with:

  • inhibitors to coagulation factors VIII or IX
  • congenital FVII deficiency
  • Glanzmann’s thrombasthenia
  • antibodies to GPIIb-IIIa or HLA
  • past or present refractoriness to platelet transfusions.


Factor VIII inhibitor bypassing agent (FEIBA) is a plasma-derived product used:

  • to control spontaneous bleeding episodes
  • in surgery for haemophilia A and B patients with inhibitors.


HELIMBRA is used is used to treat patients with:

  • severe or moderate haemophilia A
  • haemophilia A with inhibitors.


Fibrinogen concentrate (RiaSTAP) is used for the treatment of acute bleeding (including prophylaxis for high-risk patients) in patients with congenital fibrinogen deficiency.

Prothrombin complex

Prothrombin complex is a plasma-derived product used to prevent and treat bleeding patients with:

  • acquired prothrombin complex factor deficiency
  • single or multiple congenital deficiency of factor II, VII, IX or X.

Antithrombin III

Antithrombin III is a plasma-derived product that may be used before surgery or during pregnancy and childbirth for patients with an inherited deficiency of antithrombin III.

Protein C

Protein C concentrate is a plasma-derived product for patients with severe congenital protein C deficiency. It can prevent and treat venous thrombosis and purpura fulminans (blood spots, bruising and discolouring to skin as a result of the clotting of small blood vessels).


Fibrogammin is a purified concentrate of blood coagulation factor XIII derived from human plasma. It's used for:

  • congenital deficiency of factor XIII and resulting haemorrhagic diathesis, haemorrhages and disturbances in wound healing
  • haemorrhagic diatheses caused completely or in part by acquired factor XIII deficiency
  • supportive therapy for wound healing after surgery or injuries.

Factor XI and factor XIII

These plasma-derived clotting factor concentrates are used to treat patients with deficiency of the relevant clotting factor.

C1 esterase inhibitor

C1 esterase inhibitor concentrate derived from human plasma is available for patients with Type I and Type II hereditary angioedema:

  • to treat acute attacks
  • as a short-term prophylaxis for high-risk procedures such as dental work, head or neck surgery, or surgery requiring intubation
  • as a long-term prophylaxis for those who experience an average of 8 or more acute attacks a month.

Get in touch

If you have a query about clotting factor and other blood products in Australia, please contact us.

Last updated: 27 Mar 2024

Back to top